Welcome to our dedicated page for Mannatech SEC filings (Ticker: MTEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mannatech, Incorporated (NASDAQ: MTEX) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. Mannatech is a global health and wellness company that develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products through a network of independent associates and preferred customers in multiple international markets.
Here, users can review Mannatech’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which include detailed discussions of net sales by region (Americas, Asia/Pacific, EMEA), gross profit, commission and incentive expenses, selling and administrative costs, and income or loss from operations. These filings also describe the company’s use of non-GAAP Constant dollar measures that adjust for foreign currency translation, as well as risk factors related to competition, regulatory changes, economic conditions, and trade policies.
Stock Titan surfaces current reports on Form 8-K that Mannatech files to announce material events, such as quarterly financial results, leadership changes, and board or governance updates. These 8-K filings often attach the full earnings press releases as exhibits, providing additional narrative and data tables.
With real-time updates from EDGAR and AI-powered summaries, this page helps users quickly interpret lengthy Mannatech filings by highlighting key metrics, changes in financial condition, and notable disclosures. Investors can also use the filings feed to monitor items such as debt arrangements, notes payable, and other balance sheet developments that appear in Mannatech’s periodic reports and related documents.
Mannatech, Incorporated reported weaker results for the fourth quarter and full year 2025. Fourth quarter 2025 net sales were $26.6 million, down 8.2% from 2024, and the company swung from operating income to an operating loss of $0.2 million. Fourth quarter net loss was $11.3 million, or $5.94 per diluted share, compared with net income of $2.3 million a year earlier, largely reflecting unfavorable foreign currency effects and tax items.
For the year ended December 31, 2025, net sales declined to $108.0 million, down 8.3%, with constant-currency sales down 6.8%. Gross margin slipped to 74.9% as supply chain pressures raised product and freight costs. The company posted an operating loss of $0.4 million versus operating income of $1.4 million in 2024.
Full-year net loss was $15.2 million, or $8.00 per diluted share, driven mainly by an income tax provision of $12.3 million, including a non-cash deferred tax charge of $11.5 million. Cash and cash equivalents were $6.2 million at December 31, 2025, and total shareholders’ equity moved to a deficit of $5.2 million.
Mannatech, Incorporated outlines its global wellness business, selling proprietary nutritional supplements, weight-management and skin care products primarily through a network marketing model. The company operates across the Americas, EMEA and Asia/Pacific, and also runs a cross-border e-commerce business in China via its Meitai subsidiary.
As of December 31, 2025, Mannatech reports about 114,000 active associate and preferred customer positions, and notes that commissions and incentives typically range from 35% to 43% of consolidated net sales. The company relies heavily on key products such as Ambrotose Life, TruHealth and Optimal Support Packets and had 170 employees in 2025, down from 189 in 2024.
The report highlights extensive regulatory oversight in the United States and numerous foreign jurisdictions, dependence on third‑party manufacturers and certain unique ingredients, competitive pressure in the nutrition and direct selling industries, and growing risks related to information technology, data protection and the use of artificial intelligence.
Mannatech, Incorporated disclosed that it filed a Form 12b-25 to delay its Annual Report on Form 10-K for the year ended December 31, 2025. The company said it could not complete the filing within the normal deadline without unreasonable effort or expense.
Its independent auditor has discussed with management the possibility of a going concern issue, and management needs more time to assess the repercussions and any necessary remediation, including consulting third-party tax advisors and reviewing a cost-reduction plan. Mannatech currently expects to file the 2025 Form 10-K within the 15-day extension period allowed under Rule 12b-25 and targets filing by April 15, 2026.
Mannatech, Incorporated reported a planned leadership change in its finance organization. After a mutual discussion, the company notified Chief Financial Officer James Clavijo on March 19, 2026 that his employment agreement will not be renewed when it expires on June 30, 2026. Under his agreement, he will continue to receive base salary for three months after the term ends, providing a short transition period.
To maintain continuity in financial oversight, the Board appointed Yasir Haider, the company’s Controller, as Interim CFO effective March 20, 2026. Haider joined Mannatech on January 6, 2025 and brings prior experience as a Chief Financial Officer and Financial Controller, with responsibilities over global financial operations, multi-entity consolidations, SEC reporting, mergers and acquisitions, and capital planning. He also holds an MBA from West Texas A&M University.
Mannatech, Inc. director Larry A. Jobe reported acquiring additional common stock of the company. On January 2, 2026, he acquired 4,790 shares of Mannatech common stock at a price of $8.35 per share. After this transaction, he directly beneficially owned 62,197 shares of Mannatech common stock. The filing indicates this was a direct ownership position by a director, reflecting an increase in his equity holdings in the company.
Mannatech, Incorporated filed an 8-K stating it issued a press release announcing financial and operating results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 titled “Mannatech Reports Financial Results for Third Quarter 2025.”
The filing uses Item 2.02 to note the results announcement and provides the related materials, including the Inline XBRL cover page file. Specific revenue, earnings, or guidance figures are contained in the attached press release rather than this notice.
Mannatech (MTEX) filed its Q3 2025 report, showing improved profitability despite softer sales. Net sales were $29.2 million, down 8.1% year over year, but gross margin improved to 76.4% as costs eased. Operating income rose to $2.0 million from $0.9 million. Other income benefited from foreign currency, contributing $0.6 million, and net income reached $1.9 million, or $1.01 per diluted share, versus a loss a year ago.
For the first nine months, net sales were $81.4 million, down 8.4%. The company reported a net loss of $3.9 million, or $2.06 per share, with a $2.6 million realized and unrealized foreign currency loss weighing on results. Cash and cash equivalents were $7.1 million as of September 30, 2025, compared with $11.4 million at year-end, and operating cash flow for the period was negative $2.7 million. Notes payable totaled $2.9 million at a 16% rate, with maturities extended to March 31, 2027.
Asia/Pacific led Q3 with 64.4% of sales, followed by the Americas at 27.1% and EMEA at 8.5%. Shares outstanding were 1,900,930 as of November 4, 2025. Inventory was $11.1 million and deferred revenue tied to loyalty programs ended at $2.3 million.
James Clavijo, Chief Financial Officer and director of Mannatech Inc. (MTEX), filed an amended Form 4 to report a grant of 10,000 stock options on 06/03/2025. The options carry an exercise price of $10.60 and an expiration date of 06/03/2035. The amendment corrects the vesting schedule: one-third vests on each anniversary of the grant over three years, with all options vesting immediately upon a change in control. After the reported transaction, Mr. Clavijo directly beneficially owns 14,500 shares. The amendment was filed because the original Form 4 misstated the vesting schedule.